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Introduction
CM is a complex neurological disorder affecting approxi-
mately 2% of the general adult population. CM sufferers
experience a broad range of debilitating symptoms.
Objective
To assess the daily headache symptoms of chronic
migraine (CM) patients over a 4-week period.
Design/methods
PREEMPT (two phase 3 studies: 24-week, double-blind,
placebo-controlled, parallel-group phase, followed by 32-
week, open-label phase) evaluated onabotulinumtoxinA
for prophylaxis of headaches in CM (>15 days/month
with headache lasting >4 hours/day). A total of 1384
CM patients daily reported their headache symptoms
for a 28-day baseline period using an interactive voice
response telephone diary. The baseline frequencies of
various headache features and associated symptoms
were computed.
Results
Of 38,752 total days, patients reported 27,483 (70.9%)
days with >4 hours of headache. Patients classified their
pain as moderate/severe on 90.9% of their headache-
days. The most common associated symptoms patients
described experiencing on headache-days were photo-
phobia (81.2%), phonophobia (80.2%), exacerbation with
physical activity (80.0%), pulsating quality (70.8%), uni-
lateral pain (63.6%), and nausea (59.8%). Vomiting
(13.8%) was reported infrequently.
Conclusion/relevance
These CM patients experienced severe headache symp-
toms throughout the 28-day baseline period. The over-
whelming majority of headaches were characterized as
moderate/severe pain intensity, which were often
accompanied with sensitivity to both light and sound
and aggravated by routine physical activity. The majority
of patients also reported pulsating pain quality, unilat-
eral headache, and nausea. The heavy burden of illness
suffered by CM patients emphasizes the necessity of
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